Pharmaceutical company Novo Nordisk has awarded its U.S. media assignment to Omnicom following a review, the company has confirmed.  

The firm spends upwards of $600 million annually on media, according to agency research firm COMvergence. 

The firm previously worked with WPP on the account. WPP's Wavemaker was awarded U.S. duties in 2020 after a review.  

There were rumors circulating earlier this week that NN had completed the review and that Omnicom came out on top. However, at the time a spokesman for the pharma company said that no award had been announced to the contenders. That was late Tuesday afternoon. 

But now the appointment is official. Here's the company's statement:  

"Novo Nordisk has selected Omnicom as our agency-of-record to manage media buying in the U.S. beginning in Q4 2026.  

"We look forward to working with the Omnicom team as we continue to scale consumer-focused strategies and connect with patients through emerging channels and technologies, helping bring even greater awareness of our medicines to people living with chronic conditions such as obesity and diabetes." 

Last month Novo Nordisk filed a lawsuit against rival pharma company Eli Lily for allegedly false GLP-1 advertising. The two companies are fierce competitors in the GLP-1 weight loss drug category. NN founded the category with the launch of Wegovy and Lily followed with Zepbound.